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Introduction: Immunoglobulin G4 (IgG4)–related aortitis/periaortitis and periarteritis are vascular manifestations of
IgG4-related disease. In this disease, the affected aneurysmal lesion has been suspected to be at risk of rupture. In
this study, we aimed to clarify the clinical course after corticosteroid therapy in IgG4-related aortitis/periaortitis
and periarteritis.
Methods: We retrospectively evaluated clinical features, including laboratory data, imaging findings and the course
after corticosteroid therapy, in 40 patients diagnosed with IgG4-related aortitis/periaortitis and periarteritis on the
basis of periaortic/periarterial radiological findings, satisfaction of the comprehensive diagnostic criteria or each
organ-specific diagnostic criteria, and exclusion of other diseases.
Results: The patients were mainly elderly, with an average age of 66.4 years and with a marked male
predominance and extensive other organ involvement. Subjective symptoms were scanty, and only a small
proportion had elevated serum C-reactive protein levels. The affected aorta/artery were the abdominal aortas or
the iliac arteries in most cases. Thirty-six patients were treated with prednisolone, and the periaortic/periarterial
lesions improved in most of them during the follow-up period. Two (50.0%) of four patients with luminal
dilatation of the affected lesions before corticosteroid therapy had exacerbations of luminal dilatation after
therapy, whereas none of the twenty-six patients without it had a new appearance of luminal dilatation
after therapy.
Conclusions: The results of this retrospective multicenter study highlight three important points: (1) the
possibility of latent existence and progression of periaortic/periarterial lesions, (2) the efficacy of corticosteroid
therapy in preventing new aneurysm formation in patients without luminal dilatation of periaortic/periarterial
lesions and (3) the possibility that a small proportion of patients may actually develop luminal dilatation of
periaortic/periarterial lesions in IgG4-related aortitis/periaortitis and periarteritis. A larger-scale prospective study
is required to confirm the efficacy and safety of corticosteroid therapy in patients with versus those without
luminal dilatation and to devise a more useful and safe treatment strategy, including administration of other
immunosuppressants.* Correspondence: sk33166@gmail.com
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Immunoglobulin G4 (IgG4)–related disease (IgG4-RD) is a
recently recognized systemic inflammatory disease with
multiorgan involvement [1-3]. IgG4-RD is characterized by
tumefactive lesions, a dense lymphoplasmacytic infiltration
with abundant IgG4-positive plasma cells, storiform fibrosis
and elevated serum IgG4 levels. Writing from a patho-
logical viewpoint, Stone et al. [4] and Kasashima et al. [5,6]
described some patients with chronic aortitis/periaortitis or
inflammatory aortic aneurysm as also having an IgG4-
related condition. Microscopically, these lesions have a pre-
dilection for the adventitia and periaortic/periarterial
tissue, although they also affect the media, indicating
the disease have not just a periaortitis component but also
an aortitis one [4-9]. In addition, Inoue et al. reported
characteristic computed tomography (CT) findings of 17
Japanese patients with IgG4-related periaortitis and/or
periarteritis. Macroscopically, this disease represents peri-
aortic or periarterial, circumferential or partial, thickened
or masslike lesions with or without aneurysmal change
[10]. Presumably, IgG4-related periaortitis and periarteritis
may have some overlap with IgG4-related retroperitoneal
fibrosis. Inoue et al. proposed that this discrimination is
dependent on the predominant location of the lesions.
They deemed periaortitis appropriate to refer to lesions
with predominant periaortic and concentric involvement,
whereas periureteral or plaquelike lesions should be re-
ferred to as retroperitoneal fibrosis [10]. In this context,
the concept of IgG4-related aortitis/periaortitis and periar-
teritis (PAo/PA) has been proposed [9]. However, the clin-
ical characteristics and course after corticosteroid therapy
in patients with IgG4-related PAo/PA have not been well-
clarified. Moreover, although corticosteroid therapy has
been suspected to increase the risk of aneurysm formation
or rupture [5,8,10], the precise incidence of these compli-
cations and their timing in the clinical course have not
been elucidated.
This state of affairs prompted us to undertake the
present study to clarify the clinical characteristics and




From among 333 patients with IgG4-RD at Kanazawa
University Hospital, Sapporo Medical University Hospital,
Nagaoka Red Cross Hospital, Toranomon Hospital,
Toyama University Hospital and Kanazawa Medical
University Hospital between 1 January 1995 and 30
September 2013, we identified 40 with IgG4-related
PAo/PA (Table 1). The diagnosis of this disease was
made on the basis of the presence of consistent periaor-
tic/periarterial radiological findings, the fulfillment of
the published comprehensive diagnostic criteria (CDC)[11] or each organ-specific diagnostic criteria [12-14] and
exclusion of other diseases. The diagnosis of extravascular
lesions was made on the basis of physical examination, im-
aging findings and/or histopathological examination, in
addition to exclusion of other conditions. According to
the CDC, 25 patients (patients 2 through 5, 7, 8, 10, 11, 13
through 17, 19, 21 through 23, 26 through 28, 32, 34
through 36 and 38 in Table 1) were diagnosed with defin-
ite IgG4-RD, three (patients 1, 9 and 37) with probable
IgG4-RD and 12 (patients 6, 12, 18, 20, 24, 25, 29 through
31, 33, 39 and 40) with possible IgG4-RD. Three (patients
6, 18 and 29) of these twelve patients fulfilled the revised
diagnostic criteria for autoimmune pancreatitis (AIP) [13].
Well-experienced physicians of this disease diagnosed the
remaining nine patients with IgG4-RD on the basis of a
consistent clinical picture with elevated serum IgG4 con-
centrations and exclusion of other diseases. Twenty-nine
(80.6%) of thirty-six patients who had extravascular IgG4-
related organ involvement underwent biopsy of affected
organs and showed histologically typical light micro-
scopic findings [15] and copious IgG4-positive plasma
cell infiltration. Histological evaluation of periaortic/peri-
arterial lesions was performed in only one patient (patient
37) by means of incisional biopsy of the periaortic mass le-
sions, which did not show any vascular structures but
histological findings compatible with IgG4-related retro-
peritoneal fibrosis. We retrospectively evaluated baseline
clinical features, including subjective symptoms, labora-
tory data and imaging findings, in these 40 patients. Be-
cause follow-up data were absent or inadequate for seven
patients (patients 1, 2, 21, 33, 37, 39 and 40), we limited
the analysis of the clinical course to the remaining thirty-
three patients (Figure 1). Two patients (patients 8 and 17)
had been included in earlier studies ([16] and [17],
respectively).
This study was approved by the Medical Ethics Commit-
tee of Kanazawa University, the institutional review board
of Sapporo Medical University Hospital, the Ethics Com-
mittee of Nagaoka Red Cross Hospital, the institutional re-
view board of Toranomon Hospital, the review board of
the University of Toyama and the Research Ethics Com-
mittee of Kanazawa Medical University. Informed consent
for publication of all data and samples was obtained from
each patient. The research was conducted in compliance
with the Declaration of Helsinki.
Imaging evaluation
All patients underwent whole-body CT examinations at
the time of the initial diagnosis, and follow-up CT data
were available for 33 patients, 31 of whom received cor-
ticosteroid therapy. All imaging data were reviewed by a
single radiologist with extensive experience in IgG4-RD at
Kanazawa University Hospital. Periaortic/periarterial lesions
were described as circumferential or partial thickened wall









Follow-up IgG IgG4 IgE CRP Extravascular lesions
Patient (mo) (mg/dl) (mg/dl) (IU/ml) (mg/dl) Symptoms
1 204 1,894 128 543 6.2 AA (−) La, Sa abdo P, fever (−) 30
2 120 2,840 693 468 0.1 AA (−) Sa (−) DM, Sm 30
3 96 5,970 3,100 259 1.56 AA (−) La, Sa, Hy, Pa malaise DM, HT 40
4 78 2,140 557 266 <0.10 AA, IA (+) La, Sa (−) DL, Sm 50
5 70 1,500 173 151 0.3 IA, SMA (−) Pa, RF abdo P DM, HT, DL, Sm 20
6 63 2,970 1,330 419 <0.10 AA (−) La, Sa, Pa, Ki, RF malaise DM, HT, DL, Sm 40
7 63 2,130 715 253 <0.10 IA (−) La, Sa (−) DM, DL, Sm 40
8 63 2,731 269 975 0.6 AA (−) Sa, RF (−) DM, HT, DL, Sm 30
9 57 1,790b 105b 212b 1.5b AA, IA (+) Hy, Lu, Pa, Ly (−) DL 40
10 54 2,570 1,420 345 0.3 AA, IA (+) Pa (−) DM, HT 20
11 48 2,950 1,540 7.9 <0.1 AA (−) Sa, Bi, Pa, Pr (−) DM 30
12 43 1,487 196 447 0.6 AA, IA (−) RF abdo P DM, HT, DL, Sm 0
13 37 2,563 1,330 283 0.09 AA (−) Sa, Ki pollakiuria DL, Sm 45
14 35 2,319 734 542 1.19 TA, AA (−) Sa, Pa, Ki (−) DM, DL 40
15 34 1,458 158 452 0.22 AA (−) Sa, Ly (−) DM, HT, DL, Sm 30
16 27 2,081 870 1,285 0.0 AA, IA (−) Sa, RF, Pr (−) DM, HT 20
17 27 1,756 408 513 0.2 AA, IA (−) Sa, Pa, Ki (−) DM, HT, DL, Sm 20
18 27 1,762 144 24 0.32 AA, IA (+) Pa (−) DL, Sm 20
19 25 2,024 292 1,400 0.14 AA (−) Pa, RF (−) DM, HT, Sm 40
20 24 2,262 299 443 <0.05 AA (−) (−) (−) HT 0
21 24 2,184 236 365 0.3 AA (+) La, Sa fever DM, HT, DL 30
22 22 3,484 1,896 247 0.0 AA (−) La, Sa, Pa, Ki, Ly (−) Sm 35
23 15 4,171 2,120 <20 0.32 AA, IA (−) La, Sa, Ki (−) DM, HT, Sm 40
24 13 1,837 261 687 0.06 IA (−) RF (−) HT, DL 30
25 13 1,454 196 350 0.13 AA, IA (−) (−) abdo P Sm 15
26 10 2,213 455 NA 0.56 AA, IA (−) Sa, Ki arthralgia HT, DL, Sm 40
27 10 3,120 1,020 1,760 1.5 AA, IA, IMA (−) La, Sa hoarseness, fever Sm 30
28 9 2,936 1,070 17 0.0 TA, AA, IA (−) La, Sa, Pa, Ki thirst DM, DL, Sm 40
29 9 10,121 2,500 <20 0.37 IA (+) Pa, Ki, Ly malaise DM 50

















Table 1 Baseline characteristics of 40 patients with IgG4-related aortitis/periaortitis and periarteritis (Continued)
31 8 1,475 210 111 0.3 IA (−) Sa (−) (−) 40
32 4 2,938 1,520 48 0.1 AA (−) La, Sa, Ki, RF (−) Sm 30
33 4 1,463 672 216 0.13 AA (−) Sa, Pl, Ca (−) Sm 0
34 3 2,439 782 703 0.2 AA, IA (−) La, Ki, RF (−) DM, DL, Sm 20
35 3 2,244 503 311 0.0 AA, IA (−) Ki edema (−) 30
36 2 1,950 711 737 0.0 AA (−) La, Sa, Lu, Ki (−) Sm 35
37 2 1,328 106 19 0.28 AA, IA (+) RF (−) DL 0
38 1 4,420 2,680 174 0.1 IA (−) La, Sa, Bi, Pa, Ki, Ne diarrhea Sm 50
39 1 2,276 835 <20 0.91 IA (−) Sa (−) HT 15
40 1 1,600 206 212 0.38 AA (−) (−) abdo P, malaise Sm 30
AA, Abdominal aorta; abdo, Abdominal; Bi, Bile tract; Ca, Pericarditis; CRP, C-reactive protein; DL, Dyslipidemia; DM, Diabetes mellitus; F, Female; HT, Hypertension; Hy, Hypophysitis; IA, Iliac artery; IgE, Serum immunoglobulin E
at diagnosis; IgG, Serum immunoglobulin G at diagnosis; IgG4, Serum immunoglobulin G4 at diagnosis; IMA, Inferior mesenteric artery; Ki, IgG4-related kidney disease; La, Lacrimal gland, Lu, Lung; Ly, Lymph node; M, Male; Mo,
month; NA, Not available; Ne, Nerve; P, Pain; Pa, Pancreas; Pl, Pleuritis; Pr, Prostate; PSL, Prednisolone; RF, Retroperitoneal fibrosis; Sa, Salivary gland; Sm, Past or current smoking; SMA, Superior mesenteric artery; TA, Thoracic

















Figure 1 Flowchart of participants through the study. CS, corticosteroid; IgG4-RD, IgG4-related disease; Tbc, tuberculosis; Tx, treatment.
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ment visualized by contrast-enhanced CT. At the time of
diagnosis, we also evaluated the findings of 2-[18F]-fluoro-
2-deoxy-D-glucose positron emission tomography/com-
puted tomography (FDG-PET/CT) for 20 patients and of
gallium scintigraphy for 12 patients.
At the time of initial diagnostic CT imaging, after noting
the affected site of aortas/arteries and extravascular le-
sions, we measured the maximum vascular wall thickness
and diameter of the lumen in both affected and adjacent
sites in each lesion. These two values were then longitu-
dinally evaluated in the 33 patients whose follow-up im-
aging and clinical course information were available.
Improvement and relapse of periaortic/periarterial le-
sions during the clinical course were defined as decrease
and reincrease of vascular wall thickness, respectively, at
the same site as the maximum vascular wall thickness
measured at the time of initial diagnosis. Luminal dilata-
tion of periaortic/periarterial lesions was defined as being
present when the luminal diameter of the affected site was
more than 3 mm larger than that of adjacent normal sites.
Exacerbation of luminal dilatation was defined as being
present when more than 5-mm expansion of the luminal
diameter was observed at the same site as the luminal dila-
tation detected at the time of initial diagnosis.Statistical analysis
Statistical analysis was performed using SPSS version 19
software (IBM SPSS, Chicago, IL, USA). The significance
of differences between groups was determined using
Mann–Whitney U test or Wilcoxon signed-rank test,
and the significance of differences in frequencies was
analyzed with Fisher’s exact probability test. Data are
presented as means ± SD. Significant differences were
defined as P < 0.05.
Results
Baseline characteristics
The baseline clinical characteristics of 40 patients are
shown in Table 1. Our patient group was composed of
37 men and 3 women with an average age of 66.4 ± 7.1
years (age range, 44 to 75). One patient (patient 9 in
Table 1) had been treated with prednisolone (PSL) at a
dose of 5.0 mg/day for type 1 AIP. None of the other 39
patients had been treated with any immunosuppressants,
including corticosteroids, before their diagnosis. Thirty-six
patients (90.0%) had more than one IgG4-related extravas-
cular lesion (average, 2.3 ± 1.5 organs; range, 0 to 6 or-
gans). Involvement of the salivary gland was observed in
25 patients (62.5%), lacrimal gland in 14 (35.0%), pancreas
in 14 (35.0%), kidney in 13 (32.5%), retroperitoneum in 13
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biliary tract and hypophysis in 2 each (5.0%). The fre-
quency of subjective symptoms was low (fever, 10.0%;
abdominal pain, 12.5%; general malaise, 12.5%). Moreover,
five of seven patients with luminal dilatation of the af-
fected lesions at the time of diagnosis complained of no
subjective symptoms. With regard to the major risk fac-
tors of atherosclerosis, diabetes mellitus (DM) was
present at the time of diagnosis in 20 patients (50.0%),
hypertension (HT) in 17 (42.5%), dyslipidemia (DL) in
18 (45.0%), current smoking in 9 (22.5%) and past
smoking in 15 (37.5%). The mean follow-up period of
all 40 patients after diagnosis was 33.9 ± 39.8 months
(range, 1 to 204 months).
At diagnosis, 37 (92.5%) of 40 patients showed ele-
vated serum IgG4 levels exceeding 135 mg/dl (average,
815 ± 771 mg/dl; range, 105 to 3,100 mg/dl). Thirty-one
(77.5%) of forty patients showed elevated serum IgG
levels (average, 2,551 ± 1,543 mg/dl; range, 1,200 to
10,121 mg/dl; normal range, 870 to 1,700 mg/dl). Twenty-
three (60.5%) of thirty-eight evaluated patients showed ele-
vated serum IgE levels (average, 403 ± 398 IU/ml; range,
7.9 to 1,760 IU/ml; normal range, <250 IU/ml). Although
none of the patients had leukocytosis, 16 (41.0%) of 39
evaluated patients had eosinophilia (eosinophils >5%). Six
(15.4%) of thirty-nine evaluated patients had hypocomple-
mentemia. Antinuclear antibodies were positive in 16
(40.0%) of 40 patients and the rheumatoid factor in only 3
(8.1%) of 37 evaluated patients. Myeloperoxidase antineu-
trophil cytoplasmic antibodies (ANCAs) and proteinase 3
ANCAs were not observed in any of the evaluated patients
(21 and 14 patients, respectively). Only six (15.0%) of forty
patients had elevated serum C-reactive protein (CRP) level
(CRP >1 mg/dl).
Treatment
The respective attending physicians decided the indica-
tions for treatment and the treatment regimen. Thirty-
six of forty patients were treated with PSL at an average
initial dose of 32.6 ± 9.7 mg/day (range, 15 to 50 mg/
day) for the lesions associated with IgG4-RD. Only one
patient (patient 1 in Table 1) received cyclophosphamide
in addition to PSL. Endovascular aortic repair (EVAR)
was performed for the periaortic lesions with marked lu-
minal dilatation before corticosteroid therapy in one pa-
tient (patient 18) to prevent rupture. We excluded five
patients (patients 1, 2, 21, 39 and 40) from the analysis
of the clinical course because their follow-up imaging
data were not available. During the clinical course of the
other 31 patients, the initial PSL dose was generally con-
tinued until 2 to 4 weeks after the start of therapy and
then gradually tapered. The PSL dose was tapered to 5
to 10 mg/day by 12 months in 18 (94.7%) of 19 patients
whose follow-up period was more than 12 months. Theaverage PSL dose at the last review was 10.0 ± 9.2 mg/
day. Because one patient (patient 12) showed strong
positivity in the tuberculin skin test and interferon γ re-
lease assays, he was treated with antituberculosis therapy
only. The other three patients (patients 20, 33 and 37)
were observed without any treatment (Figure 1).
Radiological findings at diagnosis
CT images revealed thickened lesions surrounding the
aorta/artery in all patients. The affected aorta/artery data
were for two thoracic aortas (Figure 2A), thirty-three ab-
dominal aortas (Figure 2C), twenty-three iliac arteries
(Figure 2E), one superior mesenteric artery (Figure 2G)
and one inferior mesenteric artery. All 33 abdominal
aortic lesions affected the infrarenal abdominal aorta,
and only 6 lesions also affected the suprarenal abdom-
inal aorta. CT also revealed typical extravascular lesions,
mainly in the salivary glands, lacrimal glands, pancreas
and kidney. Sixteen of twenty patients who underwent
FDG-PET/CT, and only four of twelve patients who
underwent gallium scintigraphy, showed significant up-
take of the periaortic/periarterial lesions detected by CT.
Changes in radiological findings of periaortic/periarterial
lesions after corticosteroid therapy
After corticosteroid therapy, reduction in the thickness
of the periaortic/periarterial lesions was observed during
an average follow-up period of 30.1 ± 26.2 months
(range, 1 to 96 months) in 30 (96.8%) of 31 patients
whose clinical course was analyzed (Figure 2), although
1 patient (patient 9 in Table 1) experienced relapse dur-
ing PSL tapering at a dose of 7.0 mg/day. The average
vascular wall thickness of the 34 periaortic/periarterial
lesions of 31 patients at the time of diagnosis (7.1 ± 3.0
mm; range, 3 to 18 mm) significantly decreased after
corticosteroid therapy (2.7 ± 2.0 mm; range, 1 to 9 mm)
(Figure 2I). Generally, obvious radiographic improve-
ment of more than 50% reduction in thickness was ob-
served by 2 months after the start of therapy, after which
point some patients showed further improvement and
others showed almost no change (Figure 3). Eighteen of
the thirty-four lesions had almost completely disappeared
by the time of the last review. The rate of improvement,
relapse or complete disappearance of the perivascular le-
sions did not differ significantly between the patients with
multiple versus single vascular involvement, between
those with versus without a specific other organ involve-
ment such as AIP or between the presence or absence of
any of the specific risk factors of atherosclerosis.
Luminal changes after corticosteroid therapy
Of the 31 patients whose clinical course was analyzed
after corticosteroid therapy, 5 (patients 4, 9, 10, 18 and
29 in Table 1) had luminal dilatation of the periaortic/
Figure 2 Contrast-enhanced computed tomography findings of periaortic/periarterial lesions and changes after corticosteroid therapy.
A thoracic aortic lesion (A) had slightly improved 1 month after corticosteroid therapy (B), an abdominal aortic lesion (C) and an iliac arterial
lesion (E) had almost disappeared 10 months after therapy (D and F, respectively) and a superior mesenteric arterial lesion (G) showed fair
improvement 2 months after therapy (H). Significant pre- to posttherapy decreases in maximum wall thickness of periaortic/periarterial lesions
were observed (I). Tx, Treatment.
Figure 3 Changes in maximum vascular wall thickness of periaortic/periarterial lesions after the start of corticosteroid therapy. Data for
patients who underwent follow-up computed tomography within 2 months after the start of therapy are shown.
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4C and 4E) and three (patients 10, 18 and 29) of them
were diagnosed as having inflammatory aneurysm. One
(patient 18) of them was treated with EVAR and PSL ad-
ministration and did not have exacerbation of the luminal
dilatation during the follow-up. The other four patients re-
ceived PSL administration alone, in two (patients 9 and
10) of whom (50%) the luminal dilatation was exacerbated
28 and 46 months after the start of therapy, respectively
(Figures 4B, 4D, 4F and 4G). Throughout the clinical
course, patient 9 did not have hypertension and patient 10
received antihypertensive agents, which achieved good
blood pressure control (below 140/90 mmHg). The lu-
minal diameter was stable after corticosteroid therapy in
the 26 patients without luminal dilatation at diagnosis
(Figure 4H).
Outcome of patients without corticosteroid therapy
Four patients (patients 12, 20, 33 and 37 in Table 1) did
not receive corticosteroid therapy. One patient (patient
12) treated with antituberculosis therapy had gradual im-
provement of serum IgG4 level, periaortic/periarterial le-
sions and retroperitoneal fibrosis. In another untreated
patient (patient 20), periaortic/periarterial lesion showed
no change during the 24-month follow-up period. No new
appearance of luminal dilatation was observed in these
two patients. Because follow-up imaging data of the other
patients were lacking, we excluded them from the analysis
of the clinical course.Figure 4 Exacerbation of luminal dilatation after corticosteroid therap
the periaortic/periarterial lesions at the time of diagnosis was exacerbated
of the three paired images (A and B, C and D, and E and F, respectively) h
dilatation, three lesions from two patients (red and yellow) in the maximum
observed in the 28 lesions of the 26 patients without luminal dilatation (H)Discussion
We analyzed the clinical course after corticosteroid ther-
apy in patients with IgG4-related PAo/PA. To our know-
ledge, this study is the largest to evaluate corticosteroid
safety and effectiveness in preventing new aneurysm for-
mation in patients without luminal dilatation of periaor-
tic/periarterial lesions, as well as the risk for exacerbation
of luminal dilatation of such lesions in patients with it be-
fore therapy.
Biopsy of periaortic/periarterial lesions may cause
massive hemorrhage. In our study, we could not perform
histopathological examinations of these lesions, with the
single exception of patient 37, whose specimens obtained
by incisional biopsy of periaortic mass lesions showed only
findings compatible with IgG4-related retroperitoneal fi-
brosis because of a lack of vasculature structures. To com-
pensate for this difficulty, the presence of IgG4-related
extravascular lesions, in addition to serological and typical
radiological findings, was helpful in making a diagnosis of
IgG4-related PAo/PA.
In contrast to our present study, the frequency of extra-
vascular lesions was low in several previous studies. In
those studies, periaortic/periarterial lesions were at an ad-
vanced stage with frequent aneurysmal formation, and the
diagnosis was based mainly on the histopathological find-
ings of the periaortic/periarterial lesions themselves because
surgical treatment was selected [4,6,7,18,19]. In contrast,
our cases seem to have been at an earlier stage, attributable
to the fact that the identification of extravascular lesionsy. Luminal dilatation (A and C, patient 10 in Table 1; E, patient 9) of
after corticosteroid therapy (B, D and F, respectively). Red lines in each
ave the same length. Of five lesions from four patients with luminal
luminal diameter increased (G), whereas no obvious increase was
. Tx, Treatment.
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the making of an early diagnosis.
Accordingly, in vasculature-restricted cases, the correct
diagnosis of IgG4-RD is much more difficult to make. To
diagnose such patients early, the indications and accuracy
of CT-guided biopsy of periaortic/periarterial lesions
should be investigated, the risks and benefits of a diagnos-
tic trial of corticosteroid therapy should be evaluated and
a search for other valuable and less-invasive diagnostic
markers should be undertaken. In such cases, it is of great
importance to exclude other differential diagnoses, such as
malignancy, infections, autoimmune disease and drug re-
actions, which can mimic IgG4-related PAo/PA [20,21].
A definitive therapeutic strategy for IgG4-related PAo/
PA has not been established, and to date indications for
treatment and the type of treatment regimen have been
decided by the respective attending physician. In type 1
AIP (IgG4-related pancreatitis), the pancreatic manifest-
ation of IgG4-RD, consensus guidelines for treatment,
which are based on copious clinical experience [22], have
been available since 2010 [23]. In AIP patients, corticoster-
oid administration should be employed for patients with
symptoms such as obstructive jaundice and abdominal
and back pain. The initial oral PSL dose of 0.6 mg/kg/day,
continuation of the initial dose for 2 to 4 weeks and taper-
ing by 5 mg every 1 to 2 weeks to a maintenance dose (2.5
to 5 mg/day) over a period of 2 to 3 months are recom-
mended. In our study, corticosteroid therapy was started
at an initial PSL dose of less than 30 mg/day for eight pa-
tients, 30 to 40 mg/day for twenty-four patients and over
40 mg/day for four patients. In most of the patients whose
follow-up period was more than 12 months, the PSL dose
was tapered to 5 to 10 mg/day by 12 months. In this way,
the initial therapy generally following the guidelines of
AIP and maintenance therapy with relatively slow tapering
were performed in our study, with good efficacy attained
on the whole.
The results of this study suggest that luminal dilatation
of affected lesions may actually occur during corticoster-
oid therapy in patients with IgG4-related PAo/PA. In past
studies [5,8,10], it was speculated that corticosteroid and
other immunosuppressive therapies might increase the
risk of aneurysm rupture. Actually, an IgG4-RD patient
with multiple aneurysms who died of aneurysm rupture
after high-dose corticosteroid therapy has been reported
[24]. In our present study, of 31 patients treated with cor-
ticosteroid, exacerbation of luminal dilatation were ob-
served in only 2 who had already had it before therapy.
Because blood pressure was maintained below 140/90
mmHg in these patients throughout their clinical course,
hemodynamics seemed not to have influenced the exacer-
bation of luminal dilatation in any obvious fashion. In con-
trast, no patient without luminal dilatation showed a new
appearance of it after therapy. These results suggest thatmore careful observation during corticosteroid therapy
may be necessary to detect further luminal dilatation early
in IgG4-related PAo/PA patients with preexisting luminal
dilatation. However, because no patient with luminal dila-
tation and only one patient without luminal dilatation
were observed without corticosteroid therapy, the natural
course of the disease or of preexisting dilatation was not
clarified. Moreover, the small number of patients with lu-
minal dilatation precluded statistical analysis of the influ-
ence of independent risk factors on the luminal dilatation
in IgG4-related PAo/PA. Therefore, whether preexisting
luminal dilatation, corticosteroid therapy or some other
factor is an independent risk factor for the aneurysm for-
mation or exacerbation in IgG4-related PAo/PA patients
will have to be clarified through multivariate analysis in a
larger prospective study.
This study’s results appear to support the contention
that corticosteroid therapy can prevent new appearance
of luminal dilatation in patients without it before ther-
apy. In two case reports of IgG4-related aortitis/periaor-
titis patients with ruptured aortic aneurysms [25,26],
immunosuppressive agents, including corticosteroids,
had not been administered before aneurysm rupture.
These case reports suggest that IgG4-related PAo/PA is
itself a risk for aneurysm formation resulting in rupture
when the lesions are left untreated. However, consider-
ing that no patient without luminal dilatation showed
new appearance of it after therapy in our study, it is rea-
sonable to surmise that corticosteroid therapy improves
periaortic/periarterial lesions and prevents aneurysm for-
mation at the affected site.
Therapeutic alternatives to corticosteroids have not been
well-established in IgG4-RD. In some case reports and
small case series, some oral immunosuppressive drugs, in-
cluding azathioprine [27], methotrexate [28] and myco-
phenolate mofetil [29], have been reported to be effective.
In addition, good effectiveness of rituximab, which elimi-
nates B cells by binding the cell-surface marker CD20, has
been described [30,31]. However, the efficacy of these
drugs remains to be evaluated with regard to their effect-
iveness for periaortic/periarterial lesions and their influ-
ence on luminal dilatation in IgG4-related PAo/PA.
This study has a few limitations. First, the treatment
regimen and follow-up protocols were inconsistent be-
tween patients because of its retrospective and multi-
institutional nature. Second, although this study included
more patients than past ones, the number of patients with
luminal dilatation at the time of diagnosis was small.
Third, the association between histopathological findings
and clinical features could not be evaluated, because bi-
opsy specimens for histopathological analysis of the peri-
aortic/periarterial lesions could not be procured. Fourth,
no patient with luminal dilatation at the time of diagnosis
was observed without corticosteroid therapy.
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The results of our study show the possibility of latent exist-
ence and progression of periaortic/periarterial lesions, the
efficacy of corticosteroid therapy in preventing new
aneurysm formation in patients without luminal dilatation
of periaortic/periarterial lesions, and the possibility that a
small proportion of patients may actually experience
luminal dilatation of periaortic/periarterial lesions in IgG4-
related PAo/PA. To confirm the efficacy and safety of cor-
ticosteroid therapy in patients with versus without luminal
dilatation, and to devise a more useful and safe treatment
strategy, including administration of other immunosuppres-
sants, a larger-scale prospective study is required.
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